More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints

IMpower133 trial combining Tecentriq with chemotherapy in first-line small cell lung cancer met both its OS and PFS endpoints.

More From BioPortfolio on "More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints"